SHR-A2102 + ametinib mesylate

**SHR-A2102 + ametinib mesylate** is an investigational combination therapy composed of SHR-A2102, a nectin-4–targeted antibody-drug conjugate (ADC), and ametinib mesylate, a small molecule tyrosine kinase inhibitor. SHR-A2102 is built around an IgG1 monoclonal antibody that targets nectin-4, a tumor-associated antigen, and is conjugated to a cytotoxic agent that inhibits DNA topoisomerase I, thereby delivering targeted cytotoxicity to nectin-4–expressing tumors[1][3][5]. Ametinib mesylate is an oral, highly selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, developed for the treatment of non-small cell lung cancer and other tumors with EGFR alterations. The combination leverages dual mechanisms—the targeted delivery of cytotoxin to nectin-4–positive tumor cells and the blockade of EGFR signaling pathways—to potentially enhance antitumor efficacy and overcome resistance in advanced solid tumors. This combination is being developed and clinically evaluated primarily by Shanghai Hengrui Pharmaceutical.